Oxford, AstraZeneca Vaccine Shows Promising Immune Response In Older Adults
October 26 2020 - 8:02AM
Dow Jones News
By Jenny Strasburg
LONDON--A Covid-19 vaccine developed by the University of Oxford
and AstraZeneca PLC showed a promising immune response and low
levels of adverse reactions in the elderly and older adults,
according to an interim analysis that the U.K. drug maker called
"encouraging."
The vaccine, now in late-stage human trials aimed at showing its
efficacy and safety, is a front-runner in the global sprint for a
shot to protect lives and jump-start economies hobbled by the
coronavirus pandemic.
Trials in the U.K. could produce results before year-end,
fueling hopes among scientists and government leaders that a
vaccine might be available for high-risk groups in the country by
early 2021.
The results showed positive outcomes for those aged 56 and
older, including over-70s, and were based on analysis of previously
conducted interim safety and immune-response data, AstraZeneca and
Oxford said Monday.
The elderly generally have been prone to more-severe Covid-19
symptoms compared to younger people. Thus, researchers have been
looking for evidence that a vaccine will be able to specifically
help protect this group.
"This marks a key milestone and reassures us that the vaccine is
safe for use and induces strong immune responses in both parts of
the immune system in all adult groups," an Oxford spokesman said
Monday in a statement.
Write to Jenny Strasburg at jenny.strasburg@wsj.com
(END) Dow Jones Newswires
October 26, 2020 07:47 ET (11:47 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024